Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Chao Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University …. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Resistance, Neoplasm, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian province:, Fujian provincial health technology project, Natural Science Foundation of Fuiian Province.
Abstract (Originalsprache)
This study aimed to identify key genes associated with post‐chemotherapy recurrence in gastric cancer patients. Gene expression data from multiple cohorts were analysed to determine differentially expressed genes between recurrent and non‐recurrent cases. A prognostic risk model incorporating COL8A1, HSPB7 and SLIT2 was developed and validated across six independent cohorts. The risk score demonstrated significant associations with disease‐free and overall survival, tumour grade and molecular subtypes. Notably, the risk score showed potential as a predictor of immunotherapy response, outperforming established markers such as microsatellite instability score and Epstein–Barr virus status. Analysis of the tumour immune microenvironment revealed a correlation between risk score and M2 macrophage infiltration. A nomogram integrating the risk score with clinical factors demonstrated high accuracy in predicting patient survival. Further investigation of COL8A1 revealed its significant role in gastric cancer cell proliferation, metastasis, and chemoresistance. In vitro and in vivo experiments showed that COL8A1 knockdown inhibited cancer cell growth, invasion, and metastasis while enhancing chemosensitivity. These findings provide valuable insights into the molecular mechanisms of gastric cancer recurrence and offer potential biomarkers for prognosis and treatment response prediction. The study highlights the importance of integrating genomic data with clinical information to improve patient stratification and personalised treatment strategies in gastric cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Department of Radiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medi…
ORCID-Profile: QingShui Wang
Förderung
- Joint Funds for the Innovation of Science and Technology, Fujian province:
- Fujian provincial health technology project
- Natural Science Foundation of Fuiian Province
- Fujian University of Traditional Chinese Medicine
- Joint Funds for the Innovation of Science and Technology Fuiian province
Zitieren
APA
Xu, C., He, M., Chen, H., Chi, L., Wang, X., Li, S., Wang, Q., Lin, Y., & Xue, F. (2025). Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70621
Vancouver
Xu C, He M, Chen H, Chi L, Wang X, Li S, et al. Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70621
BibTeX
@article{Xu2025,
author = {Xu, Chao and He, MuZhen and Chen, HongYuan and Chi, LiangJie and Wang, XiangYu and Li, ShuYuan and Wang, QingShui and Lin, Yao and Xue, FangQin},
title = {Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70621}
}
EUVIMED